Cipla and Stempeutics Forge Landmark Partnership to Introduce India’s First Allogeneic Stem Cell Therapy for Knee Osteoarthritis Cipla Limited a global pharmaceutical leader with a legacy of patient-centric innovation—has officially launched Ciplostem, a groundbreaking allogeneic mesenchymal stromal cell (MSC) therapy…
Alnylam Pharmaceuticals Announces Strategic Refresh of Board of Directors to Propel Next Phase of Growth Alnylam Pharmaceuticals, Inc.the global pioneer and leader in RNA interference (RNAi) therapeutics, today announced a significant strategic evolution of its Board of Directors, reflecting the…
BioNTech Secures Overwhelming Shareholder Support, Meets Minimum Condition to Complete CureVac Exchange Offer BioNTech SE announced today that it has successfully met the minimum tender condition for its exchange offer for all outstanding shares of CureVac N.V. According to official…
ICON Survey Exposes Escalating Delays in Clinical Trial Startups—Calls for Human-Centred Site Activation Solutions biotechnology, artificial intelligence, and precision medicine, the clinical trial landscape should be accelerating. Yet, a new industry survey fromICON plc (NASDAQ: ICLR)—a global leader in clinical…
Zoetis Unveils Strategic Vision for the Future of Animal Health at Innovation Webcast, Highlighting Robust R&D Pipeline and Multi-Billion-Dollar Growth Opportunities Zoetis Inc. the global leader in animal health, hosted a highly anticipated Innovation Webcast on December 3, 2025, at…
Bayer Launches Pivotal Phase III SUNFLOWER Trial to Evaluate Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia Bayer, a global pioneer in women’s healthcare, has officially initiated SUNFLOWER (Study of Understanding NAEH – treatment Efficacy of Levonorgestrel – IUS in…
Aetna Medicaid Deepens Commitment to Ending Hunger with $500,000 Investment in Community Food Organizations Nationwide In a powerful demonstration of its ongoing dedication to community health and well-being, Aetna Medicaid—part of CVS Health® (NYSE: CVS)—has announced a significant $500,000 donation…
FDA Grants Priority Review to AstraZeneca’s Baxdrostat for Hard-to-Control Hypertension—A Potential First-in-Class Therapy In a significant milestone for cardiovascular innovation, the U.S. Food and Drug Administration (FDA) has accepted AstraZeneca’s New Drug Application (NDA) for baxdrostat under Priority Review, signaling…
SCRI Unveils Groundbreaking Blood Cancer and Blood Disorder Research Through 100 Abstracts at 2025 ASH Annual Meeting In a historic showing that underscores its growing prominence in hematology research, the Sarah Cannon Research Institute (SCRI) will present 100 abstracts and…
AdvanCell Launches Pivotal Phase 2 Expansion Trial of ADVC001, a First-in-Class Targeted Alpha Therapy for Metastatic Prostate Cancer AdvanCell, a clinical-stage radiopharmaceutical company at the forefront of developing next-generation targeted alpha therapies (TATs) for oncology, has announced the initiation of…
Samsung Bioepis Launches Denosumab Biosimilars OBODENCE™ and XBRYK™ in Europe to Improve Access and Patient Outcomes Samsung Bioepis Co., Ltd., a global biopharmaceutical company recognized for its innovative work in developing biosimilars across multiple therapeutic areas, today announced the commercial…
Janux Therapeutics Reports Encouraging Interim Phase 1 Data for JANX007 in mCRPC, Highlighting Strong Efficacy and Manageable Safety Profile Janux Therapeutics, Inc. a clinical-stage biopharmaceutical company pioneering novel immunotherapies through its proprietary platforms—Tumor Activated T Cell Engager (TRACTr), Tumor Activated…
